4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia

BACKGROUND: Alirocumab and evolocumab (PCSK9-Inhibitors), are new drugs incorporated into the therapeutic arsenal for the treatment of hypercholesterolaemia, having shown effectiveness and safety in the performed clinical trials. PURPOSE: To assess the effectiveness and safety of PCSK9-Inhibitors, t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Ambel, H Quiros, Rengifo, C Donoso, Sacristán, AA García, Sesmero, JM Martinez, Barahona, A Dominguez, Suarez, S González, Gomez, P Moya, Romero, C Blazquez
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535333/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados